STOCK TITAN

Context Therapeutics Inc - CNTX STOCK NEWS

Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.

Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company pioneering T cell-engaging bispecific antibody therapies for solid tumors. This page serves as the definitive source for verified news and official updates about the company's innovative oncology pipeline, including clinical trial progress, regulatory milestones, and strategic partnerships.

Investors and researchers will find curated updates on key programs like CTIM-76 (targeting CLDN6+ cancers) and CT-95/CT-202 bispecific antibodies. All content is sourced directly from company filings and press releases, ensuring reliability for those monitoring developments in precision cancer immunotherapy.

Our news coverage focuses on three critical areas: Clinical Trial Advancements (Phase 1/2 updates, patient enrollment), Regulatory Progress (FDA communications, trial design approvals), and Strategic Collaborations (research partnerships, intellectual property developments). Each update is contextualized to show its significance within the broader oncology treatment landscape.

Bookmark this page for streamlined access to Context Therapeutics' latest developments in bispecific antibody research. Check back regularly for real-time updates on their mission to transform care for hormone-driven and treatment-resistant cancers.

Rhea-AI Summary

Context Therapeutics (CNTX) has initiated dosing in the Phase 1 clinical trial of CT-95, a mesothelin x CD3 T cell engaging bispecific antibody. CT-95 targets mesothelin-expressing cancers, which are present in approximately 30% of all cancers. This marks Context's second active clinical trial in 2025, following the CTIM-76 trial launched earlier this year.

The Phase 1 trial (NCT06756035) is designed as an open-label, dose escalation and expansion study to evaluate CT-95's safety and efficacy in patients with mesothelin-expressing advanced solid tumors, including ovarian, pancreatic, lung, and mesothelioma cancers. The dose escalation portion is expected to enroll up to 30 patients, with initial data anticipated in mid-2026.

The study will assess safety, tolerability, pharmacokinetics, and anti-tumor activity metrics including overall response rate, duration of response, and disease control rate.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
-
Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has announced its participation in multiple upcoming investor conferences in April and May 2025.

The company will participate in four major events:

  • Stifel Virtual Targeted Oncology Forum (April 8-9) featuring a presentation on April 8 at 10:00 AM ET
  • Jones Healthcare and Technology Innovation Conference in Las Vegas (April 8-9)
  • 24th Annual Needham Virtual Healthcare Conference (April 7-10)
  • Citizens Life Sciences Conference in New York City (May 7-8) with a presentation on May 8 at 2:30 PM ET

The company will conduct one-on-one meetings during all conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.95%
Tags
conferences
-
Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has announced an upcoming poster presentation at the AACR Annual Meeting 2025 in Chicago (April 25-30, 2025).

The presentation will feature data on CT-95, the company's clinical asset targeting mesothelin x CD3 TCE. The poster will specifically detail the selection methodology for the first-in-human dose of CT-95, utilizing the minimal anticipated biological effect level (MABEL) approach. The research supports a proposed clinical starting dose of 0.1 μg/kg for CT-95.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.88%
Tags
none
Rhea-AI Summary

Context Therapeutics (CNTX) reported its full year 2024 financial results and business highlights. The company ended 2024 with $94.4 million in cash, expected to fund operations into 2027. Key developments include the first patient dosed with CTIM-76 in January 2025 for CLDN6-positive cancers, acquisition of CT-95, and in-licensing of CT-202.

Financial results show R&D expenses increased to $22.7 million in 2024 from $17.8 million in 2023, primarily due to $14.75 million in research charges related to CT-95 acquisition and CT-202 licensing. The company reported a net loss of $26.7 million for 2024, compared to $24.0 million in 2023.

Upcoming milestones include first patient dosing for CT-95 in Q2 2025, initial CTIM-76 clinical data in H1 2026, and CT-95 trial data in mid-2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
-
Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on solid tumor treatments, has granted stock options to two new employees as employment inducements. The grants total 46,000 shares of common stock, awarded outside the company's 2021 Long-Term Performance Incentive Plan, complying with Nasdaq Rule 5635(c)(4).

The options were granted on February 18 and 24, 2025, with exercise prices of $0.83 and $0.8314 per share respectively, matching Context's closing stock prices on those dates. These 10-year options follow a four-year vesting schedule: 25% vests after one year, with the remaining 75% vesting in 36 monthly installments. Vesting is contingent on continued employment with Context.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced its participation in three major upcoming investor conferences in February and March 2025:

B. Riley Securities Precision Oncology & Radiopharma Conference: Two panel discussions scheduled for February 28, 2025, at 8:00 a.m. and 10:00 a.m. ET in New York

TD Cowen 45th Annual Healthcare Conference: Presentation scheduled for March 3, 2025, at 11:10 a.m. ET in Boston

Leerink Partners Global Healthcare Conference: Fireside chat scheduled for March 10, 2025, at 10:00 a.m. ET in Miami

The company will also conduct one-on-one meetings with investors at each conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
conferences
Rhea-AI Summary

Context Therapeutics (CNTX) has initiated its Phase 1 clinical trial for CTIM-76, a Claudin 6 x CD3 T cell engaging bispecific antibody, with the first patient now dosed. The trial focuses on patients with CLDN6-positive gynecologic and testicular cancers.

The open-label study will evaluate safety and efficacy in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer. The trial aims to assess safety, tolerability, pharmacokinetics, and anti-tumor activity through metrics including overall response rate, duration of response, and disease control rate. Expected to enroll up to 70 patients, the company anticipates sharing initial data in the first half of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
-
Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX) has appointed Andy Pasternak as Chairman of its Board of Directors, effective January 13, 2025, succeeding Richard Berman. Pasternak brings over 25 years of biopharmaceutical experience and currently serves as an Advisory Partner at Bain & Company.

Most recently, Pasternak was Executive Vice President and Chief Strategy Officer at Horizon Therapeutics, where he played a key role in the company's $28 billion acquisition by Amgen in 2023. His responsibilities included corporate strategy, M&A, business development, commercial development, and portfolio management.

Prior to Horizon, he served as Head of Healthcare Practice in the Americas at Bain & Company. He currently serves on the Board of Directors of Endo and is an adjunct lecturer at Northwestern University's Kellogg School of Management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
management
-
Rhea-AI Summary

Context Therapeutics (CNTX) reported Q3 2024 financial results and business updates. The company expanded its pipeline through acquisitions of CT-95 and CT-202, two T cell engaging bispecific antibodies. Cash position stood at $84.8 million as of September 30, 2024. Q3 net loss increased to $17.5 million from $5.9 million year-over-year, primarily due to R&D expenses of $16.8 million. The company expects current cash to fund operations into 2027, including Phase 1 trials for CTIM-76 and CT-95, and IND filing for CT-202.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced its participation in three major investor conferences this November. The company will present at the Guggenheim Global Healthcare Conference (November 11), UBS Global Healthcare Conference (November 13), and Stifel 2024 Healthcare Conference (November 19).

The presentations will include fireside chats and one-on-one meetings with investors. All sessions will be webcast live and available for replay for 90 days on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.5%
Tags
conferences
Context Therapeutics Inc

Nasdaq:CNTX

CNTX Rankings

CNTX Stock Data

75.63M
88.62M
2.78%
97.4%
3.29%
Biotechnology
Pharmaceutical Preparations
Link
United States
PHILADELPHIA